Effect of fluvastatin on low-density lipoprotein peak particle diameter

This publication has 14 references indexed in Scilit:

• Lipid disorders contributing to coronary heart disease: An update
  Current Problems in Cardiology, 1996
• Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS)
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
  Journal of the American College of Cardiology, 1995
• Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk
  Current Opinion in Lipidology, 1994
• Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
  Circulation, 1994
• Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)
  Metabolism, 1993
• Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia
  Atherosclerosis, 1993
• Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1991
• Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans
  Atherosclerosis, 1991